Newsroom

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated results from the pivotal Cohort 1 of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene). Data from Cohort 1, which enrolled 125 patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointments of Erik T. Goluboff, MD, MBA as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer, effective November 9, 2026. enGene's lead investigational candidate, detalimogene voraplasmid (detalimogene) is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes...

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the Company will be featured on Health Uncensored with Dr. Drew in a segment titled “Precision Oncology: Changing the Game for Metastatic Liver Cancer.” The segment is scheduled to air nationally on Sunday, November 15, 2026. A podcast is also expected to be released following the television broadcast....

PASADENA, Calif.--(BUSINESS WIRE)--Tetra Tech, Inc. (NASDAQ: TTEK), a global provider of high-end technical and engineering services, Leading with Science® in water, environment and sustainable infrastructure, today announced results for the fourth quarter and fiscal year ended September 27, 2026. Fourth Quarter Results Revenue and revenue, net of subcontractor costs (net revenue)1, in the fourth quarter totaled $1.34 billion and $1.15 billion, respectively. Net revenue increased 5% year-over-y...

CHICAGO--(BUSINESS WIRE)--HAVI and Rush University System for Health Partner to Transform Healthcare Inventory Management...

SALT LAKE CITY--(BUSINESS WIRE)--Teiko, a CLIA clinical laboratory for monitoring the immune response, announced the publication of a review paper in Bioanalysis: https://doi.org/10.1080/17576180.2026.2744519. The paper, "Application of sample stabilization and mass cytometry in global oncology trials: lessons from regulatory T cell monitoring," draws on the companies' work in the first-in-human study of roginolisib, clinical precision oncology company iOnctura's conformation-selective PI3K-delt...

SINGAPORE--(BUSINESS WIRE)--AM Best will host its annual New Zealand market briefing to discuss market trends on Thursday, 19 November 2026, in Auckland. As part of the programme, representatives from KPMG New Zealand will present a session on the implications of agentic artificial intelligence for insurers. As part of “AM Best's New Zealand Insurance Market Briefing – Auckland,” Meg Mulry, senior director, AM Best, will present an economic and geopolitical outlook, discussing the global perspe...

ABU DHABI, Emirati Arabi Uniti--(BUSINESS WIRE)--Organizzato con il patrocinio di Sua Altezza lo Sceicco Khaled bin Mohamed bin Zayed Al Nahyan, Principe ereditario di Abu Dhabi e Presidente del Consiglio esecutivo di Abu Dhabi, l'Abu Dhabi Future Health Summit 2026 si è concluso con accordi e iniziative che coprono la scoperta di farmaci, la ricerca clinica, la medicina preventiva e la salute riproduttiva, assieme a programmi di ricerca e imprenditoria che sosterranno la collaborazione oltre i...

ABU DHABI, Vereinigte Arabische Emirate--(BUSINESS WIRE)--Unter der Schirmherrschaft Seiner Hoheit Scheich Khaled bin Mohamed bin Zayed Al Nahyan, Kronprinz von Abu Dhabi und Vorsitzender des Exekutivrats von Abu Dhabi, ging der Abu Dhabi Future Health Summit 2026 mit Vereinbarungen und Initiativen zu Ende, die die Bereiche Wirkstoffforschung, klinische Forschung, Präventiv- und Reproduktionsmedizin sowie Forschungs- und Unternehmerprogramme umfassen, die die Zusammenarbeit über den Gipfel hina...

NEW YORK--(BUSINESS WIRE)--The U.S. Attorney’s Office for the Southern District of New York, in a criminal information, has alleged that the founder of the Orca Bason Fund, Vuk Vuković, misrepresented the fund’s performance to investors and prospective investors, and charged him with securities fraud and wire fraud. Approximately 50 investors in the Orca Bason Fund have engaged Herrick, Feinstein LLP, a New York law firm, and Croatian attorneys Vanja Jurić and Fran Kušeta to jointly represent t...